96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at...

por Schwarz, Tino F, Hwang, Shinn-Jang, Ylisastigui, Pedro P, Liu, Chiu-Shong, Takazawa, Kenji, Yono, Makoto, Ervin, John E, Andrews, Charles, Fogarty, Charles, Eckermann, Tamara, Collete, Delphine, de Heusch, Magali, Schrevel, Nathalie De, Salaun, Bruno, Lievens, Marc, Maréchal, Céline, Nakanwagi, Phoebe, Hulstrøm, Veronica
Publicado 2022

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

por Leroux-Roels, Isabel, Davis, Matthew G, Steenackers, Katie, Essink, Brandon, Vandermeulen, Corinne, Fogarty, Charles, Andrews, Charles P, Kerwin, Edward, David, Marie-Pierre, Fissette, Laurence, Vanden Abeele, Carline, Collete, Delphine, de Heusch, Magali, Salaun, Bruno, De Schrevel, Nathalie, Koch, Juliane, Verheust, Céline, Dezutter, Nancy, Struyf, Frank, Mesaros, Narcisa, Tica, Jelena, Hulstrøm, Veronica
Publicado 2022